<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns="http://purl.org/rss/1.0/"><channel rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/?rss=yes"><title>The Journal of Molecular Diagnostics</title><description>The Journal of Molecular Diagnostics RSS feed: Current Issue.    
 
 
 
 The Journal of Molecular Diagnostics , the official publication of the Association for Molecular 
Pathology, co-published by the American Society for Investigative Pathology, seeks to publish high quality original papers on scientific 
advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description 
and application of technological advances in the field of molecular diagnostic medicine. The editors welcome for review articles that 
contain: novel discoveries or clinicopathologic correlations including studies in oncology, infectious diseases, inherited diseases, 
predisposition to disease, or the description or polymorphisms linked to disease states or normal variations; the application of diagnostic 
methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease 
predisposition.   </description><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/?rss=yes</link><dc:publisher>Elsevier Inc.</dc:publisher><dc:language>en</dc:language><dc:rights> © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved. </dc:rights><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:issn>1525-1578</prism:issn><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:publicationDate>March 2012</prism:publicationDate><prism:copyright> © 2012 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved. </prism:copyright><prism:rightsAgent>healthpermissions@elsevier.com</prism:rightsAgent><items><rdf:Seq><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS152515781100314X/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003138/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003199/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003114/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003126/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003163/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003151/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003175/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003187/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000037/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000025/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000062/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000074/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000190/abstract?rss=yes"/><rdf:li rdf:resource="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000207/abstract?rss=yes"/></rdf:Seq></items></channel><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS152515781100314X/abstract?rss=yes"><title>Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas: A Report of the Association for Molecular Pathology</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS152515781100314X/abstract?rss=yes</link><description>
Loss-of-function defects in DNA mismatch repair (MMR), which manifest as high levels of microsatellite instability (MSI), occur in approximately 15% of all colorectal carcinomas (CRCs). This molecular subset of CRC characterizes patients with better stage-specific prognoses who experience no benefit from 5-fluorouracil chemotherapy. Most MMR-deficient (dMMR) CRCs are sporadic, but 15% to 20% are due to inherited predisposition (Lynch syndrome). High penetrance of CRCs in germline MMR gene mutation carriers emphasizes the importance of accurate diagnosis of Lynch syndrome carriers. Family-based (Amsterdam), patient/family-based (Bethesda), morphology-based, microsatellite-based, and IHC-based screening criteria do not individually detect all germline mutation carriers. These limitations support the use of multiple concurrent tests and the screening of all patients with newly diagnosed CRC. This approach is resource intensive but would increase detection of inherited and de novo germline mutations to guide family screening. Although CRC prognosis and prediction of 5-fluorouracil response are similar in both the Lynch and sporadic dMMR subgroups, these subgroups differ significantly with regard to the implications for family members. We recommend that new CRCs should be classified into sporadic MMR-proficient, sporadic dMMR, or Lynch dMMR subgroups. The concurrent use of MSI testing, MMR protein IHC, and BRAF c.1799T&gt;A mutation analysis would detect almost all dMMR CRCs, would classify 94% of all new CRCs into these MMR subgroups, and would guide secondary molecular testing of the remainder.
</description><dc:title>Relevance, Pathogenesis, and Testing Algorithm for Mismatch Repair–Defective Colorectal Carcinomas: A Report of the Association for Molecular Pathology</dc:title><dc:creator>William K. Funkhouser, Ira M. Lubin, Federico A. Monzon, Barbara A. Zehnbauer, James P. Evans, Shuji Ogino, Jan A. Nowak</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.11.001</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-18</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-18</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Special Article</prism:section><prism:startingPage>91</prism:startingPage><prism:endingPage>103</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003138/abstract?rss=yes"><title>Next-Generation Sequencing for Simultaneous Determination of Human Papillomavirus Load, Subtype, and Associated Genomic Copy Number Changes in Tumors</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003138/abstract?rss=yes</link><description>
Human papillomavirus (HPV) infection in cases of squamous cell carcinoma of the oropharynx is a powerful predictive and prognostic biomarker. We describe how the use of next-generation sequencing can provide a novel method for the detection of HPV in DNA isolated from formalin-fixed paraffin-embedded tissues. Using this methodology in a cohort of 44 head and neck tumors, we identified the samples that contained HPV sequences, the viral subtype involved, and a direct readout of viral load. Specificity of HPV detection by sequencing compared to traditional detection methods using either PCR or p16 immunohistochemistry was 100%. Sensitivity was 50% when either compared to PCR [confidence interval (CI) = 29% to 71%] or 75% when compared to p16 (CI = 47% to 91%). In addition, we demonstrate the ability of next-generation sequencing to detect other HPV subtypes that would not have been detected by traditional methods, and we demonstrated the ability to apply this method to any tumor and any virus in a panel of eight human cancer cell lines. This methodology also provides a tumor genomic copy number karyogram, and in the samples analyzed here, a lower level of chromosome instability was detected in HPV-positive tumors compared to HPV-negative tumors, as observed in previous studies. Thus, the use of next-generation sequencing for the detection of HPV provides a multiplicity of data with clinical significance in a single test.
</description><dc:title>Next-Generation Sequencing for Simultaneous Determination of Human Papillomavirus Load, Subtype, and Associated Genomic Copy Number Changes in Tumors</dc:title><dc:creator>Caroline Conway, Rebecca Chalkley, Alec High, Kenneth Maclennan, Stefano Berri, Preetha Chengot, Melissa Alsop, Philip Egan, Joanne Morgan, Graham R. Taylor, John Chester, Mehmet Sen, Pamela Rabbitts, Henry M. Wood</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.10.003</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-11</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-11</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Technical Advances</prism:section><prism:startingPage>104</prism:startingPage><prism:endingPage>111</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003199/abstract?rss=yes"><title>Detection of Hypermethylated Vimentin in Urine of Patients with Colorectal Cancer</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003199/abstract?rss=yes</link><description>
We demonstrated previously that urine contains low-molecular-weight (LMW) (&lt;300 bp), circulation-derived DNA that can be used to detect cancer-specific mutations if a tumor is present. The goal of this study was to develop an assay to detect the colorectal cancer (CRC)–associated, circulation-derived, epigenetic DNA marker hypermethylated vimentin gene (mVIM) in the urine of patients with CRC. An artificial 18-nucleotide DNA sequence was tagged at the 5′ end of the primers of the first PCR cycle to increase the amplicon size, which was then integrated into the primers of the second PCR cycle. A quantitative MethyLight PCR-based assay targeting a 39-nucleotide template was developed and used to quantify mVIM in CRC tissues and matched urine samples. mVIM was detected in 75% of LMW urine DNA samples from patients with CRC (n = 20) and in 10% of urine samples of control subjects with no known neoplasia (n = 20); 12 of 17 LMW urine DNA samples (71%) but only 2 of 17 high-molecular-weight urine DNA samples (12%) from patients with mVIM-positive tissues contained detectable mVIM, suggesting that the mVIM detected in LMW urine DNA is derived from the circulation. The detection of mVIM in urine was significantly associated with CRC compared with controls (P &lt; 0.0001, by Fisher's exact test). A potential urine test for CRC screening using epigenetic markers is discussed.
</description><dc:title>Detection of Hypermethylated Vimentin in Urine of Patients with Colorectal Cancer</dc:title><dc:creator>Benjamin P. Song, Surbhi Jain, Selena Y. Lin, Quan Chen, Timothy M. Block, Wei Song, Dean E. Brenner, Ying-Hsiu Su</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.12.003</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Technical Advances</prism:section><prism:startingPage>112</prism:startingPage><prism:endingPage>119</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003114/abstract?rss=yes"><title>A Sample Extraction Method for Faster, More Sensitive PCR-Based Detection of Pathogens in Blood Culture</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003114/abstract?rss=yes</link><description>
Three mechanistically different sample extraction methodologies, namely, silica spin columns, phenol-chloroform, and an automated magnetic capture of polymer-complexed DNA (via an Automate Express instrument), were compared for their abilities to purify nucleic acids from blood culture fluids for use in TaqMan assays for detection of Staphylococcus aureus. The extracts from silica columns required 100- to 1000-fold dilutions to sufficiently reduce the powerful PCR inhibitory effects of the anticoagulant sodium polyanetholsulfonate, a common additive in blood culture media. In contrast, samples extracted by either phenol-chloroform or the Automate Express instrument required little or no dilution, respectively, allowing for an approximate 100-fold improvement in assay sensitivity. Analysis of 60 blood culture bottles indicated that these latter two methodologies could be used to detect lower numbers of pathogens and that a growing S. aureus culture could be detected 2 hours earlier than when using silica columns. Of the three tested methodologies, the Automate Express instrument had the shortest time to result, requiring only approximately 80 minutes to process 12 samples. These findings highlight the importance of considering the mechanism when selecting a DNA extraction methodology, given that certain PCR inhibitors act in a similar fashion to DNA in certain chemical environments, resulting in copurification, whereas other methodologies use different chemistries that have advantages during the DNA purification of certain types of samples.
</description><dc:title>A Sample Extraction Method for Faster, More Sensitive PCR-Based Detection of Pathogens in Blood Culture</dc:title><dc:creator>John F. Regan, Manohar R. Furtado, Maxim G. Brevnov, Jeanne A. Jordan</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.10.001</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-13</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-13</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Technical Advances</prism:section><prism:startingPage>120</prism:startingPage><prism:endingPage>129</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003126/abstract?rss=yes"><title>Implications for Powering Biomarker Discovery Studies</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003126/abstract?rss=yes</link><description>
This study examined variations in gene expression between FFPE blocks within tumors of individual patients. Microarray data were used to measure tumor heterogeneity within and between patients and disease states. Data were used to determine the number of samples needed to power biomarker discovery studies. Bias and variation in gene expression were assessed at the intrapatient and interpatient levels and between adenocarcinoma and squamous samples. A mixed-model analysis of variance was fitted to gene expression data and model signatures to assess the statistical significance of observed variations within and between samples and disease states. Sample size analysis, adjusted for sample heterogeneity, was used to determine the number of samples required to support biomarker discovery studies. Variation in gene expression was observed between blocks taken from a single patient. However, this variation was considerably less than differences between histological characteristics. This degree of block-to-block variation still permits biomarker discovery using either macrodissected tumors or whole FFPE sections, provided that intratumor heterogeneity is taken into account. Failure to consider intratumor heterogeneity may result in underpowered biomarker studies that may result in either the generation of longer gene signatures or the inability to identify a viable biomarker. Moreover, the results of this study indicate that a single biopsy sample is suitable for applying a biomarker in non–small-cell lung cancer.
</description><dc:title>Implications for Powering Biomarker Discovery Studies</dc:title><dc:creator>Sian M. Dibben, Robert J. Holt, Timothy S. Davison, Claire L. Wilson, Janet Taylor, Ian Paul, Kieran McManus, Paul J. Kelly, Vitali Proutski, D. Paul Harkin, Peter Kerr, Dean A. Fennell, Jacqueline A. James, Richard D. Kennedy</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.10.002</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Regular Articles</prism:section><prism:startingPage>130</prism:startingPage><prism:endingPage>139</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003163/abstract?rss=yes"><title>Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003163/abstract?rss=yes</link><description>
Gene expression profiling could assist in revealing biomarkers of lung cancer prognosis and progression. The handling of biological samples may strongly influence global gene expression, a fact that has not been addressed in many studies. We sought to investigate the changes in gene expression that may occur as a result of sample processing time and conditions. Using Illumina Human WG-6 arrays, we quantified gene expression in lung carcinoma samples from six patients obtained at chest opening before and immediately after lung resection with storage in RNAlater [T1a(CO) and T1b(LR)], after receipt of the sample for histopathology, placed in RNAlater [T2a(HP)]; snap frozen [T2b(HP.SF)]; or snap frozen and stored for 1 week [T2c(HP.SFA)], as well as formalin-fixed, paraffin-embedded (FFPE) block samples. Sampling immediately after resection closely represented the tissue obtained in situ, with only 1% of genes differing more than twofold [T1a(CO) versus T1b(LR)]. Delaying tissue harvest for an average of 30 minutes from the operating theater had a significant impact on gene expression, with approximately 25% of genes differing between T1a(CO) and T2a(HP). Many genes previously identified as lung cancer biomarkers were altered during this period. Examination of FFPE specimens showed minimal correlation with fresh samples. This study shows that tissue collection immediately after lung resection with conservation in RNAlater is an optimal strategy for gene expression profiling.
</description><dc:title>Impact of Collection and Storage of Lung Tumor Tissue on Whole Genome Expression Profiling</dc:title><dc:creator>Maxim B. Freidin, Neesa Bhudia, Eric Lim, Andrew G. Nicholson, William O. Cookson, Miriam F. Moffatt</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.11.002</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-11</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-11</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Regular Articles</prism:section><prism:startingPage>140</prism:startingPage><prism:endingPage>148</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003151/abstract?rss=yes"><title>A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003151/abstract?rss=yes</link><description>
We report a freely available software program, Pyromaker, which generates simulated traces for pyrosequencing results based on user inputs. Simulated pyrograms can aid in the analysis of complex pyrosequencing results in which various hypothesized mutations can be tested, and the resultant pyrograms can be matched with the actual pyrogram. We validated the software using the actual pyrograms for common KRAS gene mutations as well as several mutations in the BRAF, GNAS, and p53 genes. We demonstrate that all 18 possible single-base mutations within codons 12 and 13 of KRAS generate unique pyrosequencing traces and highlight the distinctions between them. We further show that all reported codon 12 and 13 complex mutations produce unique pyrograms. However, some complex mutations are indistinguishable from single-base mutations. For complicated pyrograms, Pyromaker was used in two modes, one in which hypothesis-based simulated pyrograms were pattern-matched with the actual pyrograms. In a second strategy with only the pyrogram, Pyromaker was used to identify the underlying mutation by iteratively reconstructing the mutant pyrogram. Either strategy was able to successfully identify the complex mutations, which were confirmed by cloning and sequencing. Using two examples of KRAS codon 12 mutations (specifically GGT→TTT, G12F and GGT→GAG, G12E), we report which combinations of five approaches permit unambiguous mutation identification. The most efficient approach was found to be pyrosequencing with Pyromaker.
</description><dc:title>A Virtual Pyrogram Generator to Resolve Complex Pyrosequencing Results</dc:title><dc:creator>Guoli Chen, Matthew Theodore Olson, Alan O'Neill, Alexis Norris, Katie Beierl, Shuko Harada, Marija Debeljak, Keila Rivera-Roman, Samantha Finley, Amanda Stafford, Christopher David Gocke, Ming-Tseh Lin, James Richard Eshleman</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.12.001</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-02-10</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-02-10</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Regular Articles</prism:section><prism:startingPage>149</prism:startingPage><prism:endingPage>159</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003175/abstract?rss=yes"><title>Absolute and Relative Quantification of Placenta-Specific MicroRNAs in Maternal Circulation with Placental Insufficiency–Related Complications</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003175/abstract?rss=yes</link><description>
Placental insufficiency–related complications are one of the leading causes of maternal and perinatal morbidity and mortality. This study investigated the quantification of placenta-specific microRNAs (miRNAs) in the maternal circulation during gestation in a cohort of women with normally progressing pregnancies, the differentiation between placental insufficiency–related complications and normally progressing pregnancies, and the differentiation between placental insufficiency and normally progressing pregnancies during the early stages of gestation. Both absolute and relative quantification of placenta-specific miRNAs (ie, miR-516-5p, miR-517*, miR-518b, miR-520a*, miR-520h, miR-525, and miR-526a) was determined in 50 women with normally progressing pregnancies, 32 with complicated pregnancies [21 with preeclampsia with or without intrauterine growth retardation (IUGR) and 11 with IUGR], and 7 women with pregnancies at various gestational stages who later developed preeclampsia and/or IUGR using real-time PCR and a comparative CT method relative to normalization factor (ie, geometric mean of ubiquitous miR-16 and let-7d). Both quantification approaches revealed significant increases in extracellular placenta–specific miRNA levels over time in women with normally progressing pregnancies; however, they were not able to differentiate between normally progressing and complicated pregnancies at the time of preeclampsia and/or IUGR onset. Nevertheless, significant elevation of extracellular miRNA levels was observed during early gestation (ie, within the 12th to 16th weeks) in pregnancies with later onset of preeclampsia and/or IUGR. Early gestation extracellular miRNA screening can differentiate between women with normally progressing pregnancies and those who may later develop placental insufficiency–related complications.
</description><dc:title>Absolute and Relative Quantification of Placenta-Specific MicroRNAs in Maternal Circulation with Placental Insufficiency–Related Complications</dc:title><dc:creator>Ilona Hromadnikova, Katerina Kotlabova, Jindrich Doucha, Klara Dlouha, Ladislav Krofta</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.11.003</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Regular Articles</prism:section><prism:startingPage>160</prism:startingPage><prism:endingPage>167</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003187/abstract?rss=yes"><title>Stability of PCR Targets for Monitoring Minimal Residual Disease in Neuroblastoma</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157811003187/abstract?rss=yes</link><description>
In neuroblastoma (NB) patients, minimal residual disease (MRD) can be detected by real-time quantitative PCR (qPCR) using NB-specific target genes, such as PHOX2B and TH. However, it is unknown whether the mRNA levels of these targets vary either during treatment or at relapse. If marker genes are not stably expressed, estimation of MRD levels in bone marrow (BM) or peripheral blood will be hampered. We studied the stability of a panel of qPCR markers in primary tumors at diagnosis compared with i) paired metastasis (n = 7), ii) treated (n = 10), and iii) relapse (n = 6) tumors. We also compared relative expression of the targets in iv) primary tumors and BM at diagnosis (n = 17), v) BM and peripheral blood at diagnosis (n = 20), vi) BM at diagnosis and during treatment (n = 26), and vii) BM from different puncture sides (n = 110). Especially at diagnosis, PCR target expression is quite stable. Accurate quantification is possible when expression level can be related to the primary tumor; however, PCR target expression can alter on treatment and at relapse. If the median value of relative expression of a panel of PCR targets is used, most variations due to treatment and outgrowth of subclones level out, allowing for reliable application and quantification of MRD-PCR targets in NB patients.
</description><dc:title>Stability of PCR Targets for Monitoring Minimal Residual Disease in Neuroblastoma</dc:title><dc:creator>Janine Stutterheim, Lily Zappeij-Kannegieter, Ingrid Øra, Peter G. van Sluis, Johannes Bras, Emmy den Ouden, Rogier Versteeg, Huib N. Caron, C. Ellen van der Schoot, Godelieve A.M. Tytgat</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.12.002</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-16</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-16</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Regular Articles</prism:section><prism:startingPage>168</prism:startingPage><prism:endingPage>175</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000037/abstract?rss=yes"><title>Combined Molecular Gram Typing and High-Resolution Melting Analysis for Rapid Identification of a Syndromic Panel of Bacteria Responsible for Sepsis-Associated Bloodstream Infection</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000037/abstract?rss=yes</link><description>
Effective diagnosis and treatment of bloodstream infections are often hampered by a lack of time-critical information from blood cultures. Molecular techniques aimed at the detection of circulating pathogen DNA have the potential to dramatically improve the timeliness of infection diagnosis. Our aim in this study was to establish a rapid, low-cost PCR approach using high-resolution melting analysis to identify a syndromic panel of 21 pathogens responsible for most bloodstream bacterial infections encountered in critical care environments. A broad-range, real-time PCR technique that combines primers for molecular Gram classification and high-resolution melting analysis in a single run was established. The differentiation of bacterial species was achieved using a multiparameter, decision-tree approach that was based on Gram type, grouping according to melting temperature, and sequential comparisons of melting profiles against multiple reference organisms. A preliminary validation study was undertaken by blinded analysis of 53 consecutive bloodstream isolates from a clinical microbiology laboratory. Fifty isolates contained organisms that were present in the panel, and 96% of these were identified correctly at the genus or species level. A correct Gram classification was reported for all 53 isolates. This technique shows promise as a cost-effective tool for the timely identification of bloodstream pathogens, allowing clinicians to make informed decisions on appropriate antibiotic therapies at an earlier stage.
</description><dc:title>Combined Molecular Gram Typing and High-Resolution Melting Analysis for Rapid Identification of a Syndromic Panel of Bacteria Responsible for Sepsis-Associated Bloodstream Infection</dc:title><dc:creator>Hani Ozbak, Paul Dark, Satyanarayana Maddi, Paul Chadwick, Geoffrey Warhurst</dc:creator><dc:identifier>10.1016/j.jmoldx.2011.12.004</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-01-24</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-01-24</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Regular Articles</prism:section><prism:startingPage>176</prism:startingPage><prism:endingPage>184</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000025/abstract?rss=yes"><title>Reviewer Acknowledgment</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000025/abstract?rss=yes</link><description>The Editors gratefully acknowledge the generous assistance of the following reviewers who served The Journal of Molecular Diagnostics between January 1 and December 31, 2011.   Omar Abdel-Wahab</description><dc:title>Reviewer Acknowledgment</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/j.jmoldx.2012.01.001</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-03-01</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-03-01</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Reviewer Acknowledgment</prism:section><prism:startingPage>185</prism:startingPage><prism:endingPage>186</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000062/abstract?rss=yes"><title>Editorial Board</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000062/abstract?rss=yes</link><description></description><dc:title>Editorial Board</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S1525-1578(12)00006-2</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-03-01</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-03-01</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Frontmatter</prism:section><prism:startingPage>A1</prism:startingPage><prism:endingPage>A2</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000074/abstract?rss=yes"><title>Table of Contents</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000074/abstract?rss=yes</link><description></description><dc:title>Table of Contents</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S1525-1578(12)00007-4</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-03-01</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-03-01</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Frontmatter</prism:section><prism:startingPage>A5</prism:startingPage><prism:endingPage>A5</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000190/abstract?rss=yes"><title>Instructions to Authors</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000190/abstract?rss=yes</link><description></description><dc:title>Instructions to Authors</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S1525-1578(12)00019-0</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-03-01</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-03-01</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Frontmatter</prism:section><prism:startingPage>A13</prism:startingPage><prism:endingPage>A15</prism:endingPage></item><item rdf:about="http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000207/abstract?rss=yes"><title>Scientific Integrity Policy</title><link>http://www.journals.elsevierhealth.com/periodicals/jmdi/article/PIIS1525157812000207/abstract?rss=yes</link><description></description><dc:title>Scientific Integrity Policy</dc:title><dc:creator></dc:creator><dc:identifier>10.1016/S1525-1578(12)00020-7</dc:identifier><dc:source>The Journal of Molecular Diagnostics 14, 2 (2012)</dc:source><dc:date>2012-03-01</dc:date><prism:publicationName>The Journal of Molecular Diagnostics</prism:publicationName><prism:publicationDate>2012-03-01</prism:publicationDate><prism:volume>14</prism:volume><prism:number>2</prism:number><prism:issueIdentifier>S1525-1578(11)X0008-9</prism:issueIdentifier><prism:section>Frontmatter</prism:section><prism:startingPage>A16</prism:startingPage><prism:endingPage>A17</prism:endingPage></item></rdf:RDF>
